123 related articles for article (PubMed ID: 30226950)
1. Visual disturbance or central symptom like hallucination in patients treated voriconazole: report of six cases.
Kato H; Hagihara M; Hamada Y; Koizumi Y; Nishiyama N; Yamagishi Y; Matsuura K; Mikamo H
Jpn J Antibiot; 2016 Sep; 69(3):143-150. PubMed ID: 30226950
[TBL] [Abstract][Full Text] [Related]
2. An investigation of visual hallucinations associated with voriconazole administration to patients with hematological malignancies.
Sakurada H; Yasuhara K; Kato K; Asano S; Yoshida M; Yamamura M; Tachi T; Teramachi H
Pharmazie; 2016 Nov; 71(11):660-664. PubMed ID: 29441972
[TBL] [Abstract][Full Text] [Related]
3. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole-associated visual disturbances and hallucinations.
Bayhan GI; Garipardic M; Karaman K; Akbayram S
Cutan Ocul Toxicol; 2016 Mar; 35(1):80-2. PubMed ID: 25799212
[TBL] [Abstract][Full Text] [Related]
5. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
Imataki O; Yamaguchi K; Uemura M; Fukuoka N
Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of transient receptor potential melastatin 1 correlate with voriconazole-related visual adverse events.
Jiang YK; Wang RY; Wang X; Zhao HZ; Zhou LH; Huang LP; Yip CW; Cheng JH; Que CX; Jiang C; Zhu LP
Mycoses; 2020 Jun; 63(6):579-587. PubMed ID: 32222082
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of Aspergillus empyema using combined intrathoracic and intravenous administration of voriconazole: A case report.
Takatsuka H; Yamazaki S; Watanabe A; Yokoyama I; Suzuki T; Kamei K; Ishii I
J Infect Chemother; 2020 Aug; 26(8):847-850. PubMed ID: 32414688
[TBL] [Abstract][Full Text] [Related]
12. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.
Hamada Y; Seto Y; Yago K; Kuroyama M
J Infect Chemother; 2012 Aug; 18(4):501-7. PubMed ID: 22231601
[TBL] [Abstract][Full Text] [Related]
13. Positive correlation between voriconazole trough concentrations and C-reactive protein levels in patients with chronic pulmonary aspergillosis: A retrospective cohort study.
Miyakawa-Tanaka K; Suzuki J; Hirasawa Y; Nakamura S; Takeda K; Narumoto O; Matsui H
J Infect Chemother; 2023 Jul; 29(7):683-687. PubMed ID: 36965708
[TBL] [Abstract][Full Text] [Related]
14. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database.
Kato H; Shiraishi C; Hagihara M; Mikamo H; Iwamoto T
Sci Rep; 2024 May; 14(1):12519. PubMed ID: 38822123
[TBL] [Abstract][Full Text] [Related]
15. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.
Imhof A; Schaer DJ; Schanz U; Schwarz U
Swiss Med Wkly; 2006 Nov; 136(45-46):739-42. PubMed ID: 17183438
[TBL] [Abstract][Full Text] [Related]
16. Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report.
Liu X; Su H; Tong J; Chen J; Yang H; Xiao L; Hu J; Zhang L
Medicine (Baltimore); 2017 Oct; 96(42):e8039. PubMed ID: 29049191
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting voriconazole concentration to dose ratio changes according to route of administration.
Chen C; Xu T; Zhou K; Zhu S
Eur J Hosp Pharm; 2023 Dec; 31(1):31-35. PubMed ID: 35273002
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring of Oral Voriconazole in an Infant Less than Six Months of Age and Pharmacokinetics Changes Induced by Development of CYP2C19 in the Growth Process: A Novel Case Report.
Yamaguchi A; Tazawa Y; Ueki M; Yamada M; Manabe A; Sugawara M; Takekuma Y
Yakugaku Zasshi; 2023; 143(6):545-549. PubMed ID: 37258188
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Adsorptive Analyses of Administration of Oral Voriconazole Suspension via Enteral Feeding Tube in Intensive Care Unit Patients.
Tanaka R; Eto D; Goto K; Ohchi Y; Yasuda N; Suzuki Y; Tatsuta R; Kitano T; Itoh H
Biol Pharm Bull; 2021; 44(5):737-741. PubMed ID: 33952830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
